Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

Kaplan G. S., Torcun C. C., Grune T., Ozer N., KARADEMİR B.

FREE RADICAL BIOLOGY AND MEDICINE, cilt.103, ss.1-13, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 103
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.freeradbiomed.2016.12.007
  • Dergi Adı: FREE RADICAL BIOLOGY AND MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-13
  • Anahtar Kelimeler: Proteasome, Bortezomib, Carfilzomib, Chemotherapy, Neuropathy, NF-KAPPA-B, UBIQUITIN-INDEPENDENT DEGRADATION, VIVO SYNERGISTIC CYTOTOXICITY, DIAGNOSED MULTIPLE-MYELOMA, BORTEZOMIB PLUS MELPHALAN, IN-VIVO, INDUCED APOPTOSIS, BETA-CATENIN, RETINOBLASTOMA PROTEIN, SINGLE-AGENT
  • Marmara Üniversitesi Adresli: Evet

Özet

Proteasomal system plays an important role in protein turnover, which is essential for homeostasis of cells. Besides degradation of oxidized proteins, it is involved in the regulation of many different signaling pathways. These pathways include mainly cell differentiation, proliferation, apoptosis, transcriptional activation and angiogenesis. Thus, proteasomal system is a crucial target for treatment of several diseases including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes and cancer. Over the last fifteen years, proteasome inhibitors have been tested to highlight their mechanisms of action and used in the clinic to treat different types of cancer. Proteasome inhibitors are mainly used in combinational therapy along with classical chemo-radiotherapy. Several studies have proved their significant effects but serious side effects such as peripheral neuropathy, limits their use in required effective doses.